-
ICD-10-CM Codes
›
-
Q00-Q99
›
-
Q80-Q89
›
-
Q85-
›
-
2023 ICD-10-CM Diagnosis Code Q85.02
2023 ICD-10-CM Diagnosis Code Q85.02
Neurofibromatosis, type 2
2016 2017 2018 2019 2020 2021 2022 2023 Billable/Specific Code POA Exempt
- Q85.02 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
- The 2023 edition of ICD-10-CM Q85.02 became effective on October 1, 2022.
- This is the American ICD-10-CM version of Q85.02 - other international versions of ICD-10 Q85.02 may differ.
Applicable To- Acoustic neurofibromatosis
The following code(s) above
Q85.02 contain annotation back-references
Annotation Back-References
In this context, annotation back-references refer to codes that contain:
- Applicable To annotations, or
- Code Also annotations, or
- Code First annotations, or
- Excludes1 annotations, or
- Excludes2 annotations, or
- Includes annotations, or
- Note annotations, or
- Use Additional annotations
that may be applicable to
Q85.02:
Clinical Information
- A genetic condition in which tumors form on the nerves of the inner ear and cause loss of hearing and balance. Tumors may also occur in the brain and on nerves in the skull and spinal cord, and may cause loss of speech, eye movement, and the ability to swallow.
- An autosomal dominant disorder caused by mutations in the nf2 tumor suppressor gene. It is characterized by the development of peripheral and central nervous system tumors including acoustic schwannomas, neurofibromas, gliomas, and meningiomas.
- An autosomal dominant disorder characterized by a high incidence of bilateral acoustic neuromas as well as schwannomas (neurilemmoma) of other cranial and peripheral nerves, and other benign intracranial tumors including meningiomas, ependymomas, spinal neurofibromas, and gliomas. The disease has been linked to mutations of the nf2 gene (genes, neurofibromatosis 2) on chromosome 22 (22q12) and usually presents clinically in the first or second decade of life.
Present On AdmissionPOA Help
"Present On Admission" is defined as present at the time the order for inpatient admission occurs — conditions that develop during an outpatient encounter, including emergency department, observation, or outpatient surgery, are considered POA.
- Q85.02 is considered exempt from POA reporting.
ICD-10-CM Q85.02 is grouped within Diagnostic Related Group(s) (MS-DRG v40.0):
- 091 Other disorders of nervous system with mcc
- 092 Other disorders of nervous system with cc
- 093 Other disorders of nervous system without cc/mcc
Convert Q85.02 to ICD-9-CM
Code History
- 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
- 2017 (effective 10/1/2016): No change
- 2018 (effective 10/1/2017): No change
- 2019 (effective 10/1/2018): No change
- 2020 (effective 10/1/2019): No change
- 2021 (effective 10/1/2020): No change
- 2022 (effective 10/1/2021): No change
- 2023 (effective 10/1/2022): No change
- Neurofibromatosis (multiple) (nonmalignant) Q85.00
ICD-10-CM Diagnosis Code Q85.00
Neurofibromatosis, unspecified
2016 2017 2018 2019 2020 2021 2022 2023 Billable/Specific Code POA Exempt
- acoustic Q85.02
- type 2 Q85.02
ICD-10-CM Codes Adjacent To Q85.02
Q84.4 Congenital leukonychia
Q84.5 Enlarged and hypertrophic nails
Q84.6 Other congenital malformations of nails
Q84.8 Other specified congenital malformations of integument
Q84.9 Congenital malformation of integument, unspecified
Q85 Phakomatoses, not elsewhere classified
Q85.0 Neurofibromatosis (nonmalignant)
Q85.00 Neurofibromatosis, unspecified
Q85.01 Neurofibromatosis, type 1
Q85.02
Neurofibromatosis, type 2
Q85.09 Other neurofibromatosis
Q85.8 Other phakomatoses, not elsewhere classified
Q85.83 Von Hippel-Lindau syndrome
Q85.89 Other phakomatoses, not elsewhere classified
Q85.9 Phakomatosis, unspecified
Q86 Congenital malformation syndromes due to known exogenous causes, not elsewhere classified
Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.